A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)
Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Sponsor: University of Calgary
This PHASE3 trial investigates Stroke, Acute and is currently completed. University of Calgary leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jun 2022 — Apr 2024 [monthly]
Recruiting PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2019 — Dec 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Nov 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Adelaide, Australia , Barcelona, Spain , Belfast, United Kingdom , Birmingham, United Kingdom , Botucatu, Brazil , Box Hill, Australia , Brasília, Brazil , Calgary, Canada , Cambridge, United Kingdom and 37 more locations